Former active duty military and current civilian psychologist Dr Bret Moore provides tips and advice for compassionately and effectively treating returning veterans.
Read More
Long-time editorial board member Ivan Goldberg passed away on November 26, 2013. Dr. Goldberg was a psychopharmacologist in New York and the founder of the Depression Central website and one of the largest psychopharmocology listservs in the world. Dr. Goldberg joined the TCPR editorial board in 2006. He will be missed.
Read More
Varenicline (Chantix) is a nicotine partial agonist that is approved by the FDA for smoking cessation. Since July 1, 2009, the FDA has also required a “black box warning” based on postmarketing reports of adverse neuropsychiatric effects.
Read More
In November, drug giant Johnson & Johnson (J&J) and its subsidiaries agreed to pay $2.2 billion in fines and fees for wrongdoing related to kickbacks and misbranding of a number of their medications.
Read More
Despite the increased attention drawn to TBI, I often hear statements from mental health providers like, “I don’t see anybody in my clinic who has a history of TBI,” or, “People with more severe injuries don’t seek mental health services.”
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
